ClinicalTrials.gg
RecruitingNCT07426757Updated Nov 5, 2026

An Open-Label Study to Evaluate PF-07994525 in Participants With Advanced Cancers

A Phase 1 interventional study of PF-07994525 and Midazolam in Advanced Malignancies and Advanced Cancer, sponsored by Pfizer. Recruiting at 30 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-05.

Sponsored by Pfizer · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Jul 2026; still recruiting 4 months later.
Updated Nov 5, 202611 sites addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
120
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

This is an open-label, dose escalation and dose expansion study evaluating the safety, tolerability, Pharmacokinetic (PK), Pharmacodynamic (PD), and antitumor activity of PF-07994525 in participants with R/R MM.

The study will consist of 2 parts: Part 1 (Dose Escalation) will consist of PF-07994525 dose escalation to assess the safety, tolerability, and preliminary antitumor activity in participants with R/R MM. In Part 2 (Dose expansion), PF-07994525 may be evaluated in additional participants with R/R MM to further assess safety, PK, PD, and preliminary anti-tumor activity.

02

Conditions studied

  • Advanced Malignancies
  • Advanced Cancer

Keywords

  • Advanced Malignancies
  • Advanced Cancers
  • Advanced Cancer
03

In context

Lead sponsor

Pfizer is the lead sponsor of 3,337 studies on the registry; 148 are open to participants now.

Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants aged 18 years or older (or the minimum age of consent in accordance with local regulations) at the time of .
  • Prior diagnosis of MM as defined according to IMWG criteria (Rajkumar et al. 2014)

based on IMWG criteria as defined by at least 1 of the following:

  1. Serum M-protein >0.5 g/dL by serum protein electrophoresis (SPEP)
  2. Urinary M-protein excretion >200 mg/24 hours by urine protein electrophoresis (UPEP)
  3. Serum immunoglobulin Free Light Chain (FLC) ≥10 mg/dL (≥100 mg/L) AND abnormal serum immunoglobulin kappa to lambda FLC ratio (\<0.26 or >1.65)

    • Participants must be to, or intolerant to, all established therapies known to provide clinical benefit in multiple myeloma that are an appropriate therapeutic option, in the judgement of the investigator. A minimum of 3 are required.
    • (ECOG) performance status 0-1.

Exclusion criteria

Exclusion Criteria:

  • Active plasma cell leukemia, Smoldering MM, Waldenströms macroglobulinemia, Amyloidosis, POEMS Syndrome.
  • stem cell transplant within 12 weeks prior to enrollment or active (GVHD).
  • Active or suspected cerebral/meningeal disease related to the underlying .
  • Any active, uncontrolled bacterial, fungal, or viral infection, including (but not limited to) COVID-19, Virus (HBV), Virus (HCV), known or AIDS related illness, unless deemed not by the investigator (eg, onychomycosis).
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
120 participants (estimated)

Study arms

  • Experimental
    Part 1

    Monotherapy Dose Expansion

    Drug: PF-07994525 · Drug: Midazolam

  • Experimental
    Part 2

    Monotherapy Dose Escalation

    Drug: PF-07994525

Interventions

  • DrugPF-07994525

    Oral administration

  • Oral administration

06

What researchers measure

Primary outcomes

  1. Type, incidence and severity of participants with adverse events (AEs)

    Type, incidence, severity (graded by National Cancer Institute Common Terminology Criteria for Adverse Events \[NCI CTCAE\] version 5.0), timing, seriousness, and relatedness of adverse events (AEs)

    Time frame: From the first day through 30-37 days after the last study treatment, up to approximately 2 years

  2. Type, incidence and severity of participants with laboratory abnormalities

    Type, incidence, and severity (graded by NCI CTCAE version 5.0) of laboratory abnormalities

    Time frame: From the first day through 30-37 days after the last study treatment, up to approximately 2 years

  3. Number of participants with dose modifications

    Frequency of dose modifications (eg, dose delay, treatment interruptions, dose reductions, and treatment discontinuations) due to AEs

    Time frame: From the first day through 30-37 days after the last study treatment, up to approximately 2 years

  4. Part 1: Number of Participants With Dose-limiting Toxicities (DLTs)

    Occurrence of DLTs as defined by the protocol

    Time frame: Baseline to end of DLT evaluation period

  5. Part 1: Recommended Monotherapy Dose for Expansion (RDE)

    RDE will be based on cumulative safety, preliminary antitumor activity and pharmacokinetics findings

    Time frame: From the first day through 30-37 days after the last study treatment, up to approximately 2 years

  6. Part 2: Recommended Dose for future development

    Safety, and preliminary anti-tumor activity

    Time frame: From the first day through 30-37 days after the last study treatment, up to approximately 2 years

Secondary outcomes

  1. Objective response rate (ORR) per International Myeloma Working Group (IMWG) response criteria as determined by investigator.

    Time frame: Baseline until the date of the first documentation of disease progression, death, or start of new anticancer therapy (approximately 2 years)

  2. Complete response rate (CRR) per International Myeloma Working Group (IMWG) response criteria as determined by investigator.

    Time frame: Baseline until the date of the first documentation of disease progression, death, or start of new anticancer therapy (approximately 2 years)

  3. Time to response (TTR) per IMWG as determined by investigator

    Time frame: Baseline until the date of the first documentation of disease progression, death, or start of new anticancer therapy (approximately 2 years)

  4. Duration of response (DOR) per IMWG as determined by investigator

    Time frame: Baseline until the date of the first documentation of disease progression, death, or start of new anticancer therapy (approximately 2 years)

  5. Duration of complete response (DOCR) per IMWG as determined by investigator

    Time frame: Baseline until the date of the first documentation of disease progression, death, or start of new anticancer therapy (approximately 2 years)

  6. Progression-free survival (PFS) per IMWG as determined by investigator

    Time frame: Baseline until the date of the first documentation of disease progression, death, or start of new anticancer therapy (approximately 2 years)

  7. Overall survival (OS)

    Time frame: Baseline until the date of the first documentation of disease progression, death, or start of new anticancer therapy (approximately 2 years)

  8. Single, Multiple Dose and food effect: Maximum Observed Concentration (Cmax)

    Pharmacokinetic (PK) assessments for PF-07994525

    Time frame: From the first day through 30-37 days after the last study treatment, up to approximately 2 years

  9. Single, Multiple Dose and food effect: Time to Maximum concentration (Tmax)

    Pharmacokinetic (PK) assessments for PF-07994525

    Time frame: From the first day through 30-37 days after the last study treatment, up to approximately 2 years

  10. Single, Multiple Dose and food effect: AUC from time zero to time of last measurable concentration (AUClast)

    Pharmacokinetic (PK) assessments for PF-07994525

    Time frame: From the first day through 30-37 days after the last study treatment, up to approximately 2 years

  11. Single Dose and food effect: Terminal Elimination half-life (t1/2) as data permit

    Pharmacokinetic (PK) assessments for PF-07994525

    Time frame: From the first day through 30-37 days after the last study treatment, up to approximately 2 years

  12. Single Dose and food effect: AUC versus time curve from time 0 extrapolated to infinity (AUCinf) as data permit

    Pharmacokinetic (PK) assessments for PF-07994525

    Time frame: From the first day through 30-37 days after the last study treatment, up to approximately 2 years

  13. Single, Multiple Dose and food effect: apparent clearance of drug (CL/F) as data permit

    Pharmacokinetic (PK) assessments for PF-07994525

    Time frame: From the first day through 30-37 days after the last study treatment, up to approximately 2 years

  14. Single, Multiple Dose and food effect: Apparent volume of distribution during terminal phase (Vz/F) as data permit

    Pharmacokinetic (PK) assessments for PF-07994525

    Time frame: From the first day through 30-37 days after the last study treatment, up to approximately 2 years

  15. Multiple Dose: AUC at steady state over the dosing interval (AUCtau) as data permit

    Pharmacokinetic (PK) assessments for PF-07994525

    Time frame: From the first day through 30-37 days after the last study treatment, up to approximately 2 years

  16. Multiple Dose: Cmin as data permit

    Pharmacokinetic (PK) assessments for PF-07994525

    Time frame: From the first day through 30-37 days after the last study treatment, up to approximately 2 years

  17. Multiple Dose: Accumulation ratio (Rac) as data permit

    Pharmacokinetic (PK) assessments for PF-07994525

    Time frame: From the first day through 30-37 days after the last study treatment, up to approximately 2 years

  18. AUC from time zero to time of last measurable concentration (AUClast)

    PK parameters of CYP3A4 probe substrate midazolam with and without PF-07994525

    Time frame: From the first day through 30-37 days after the last study treatment, up to approximately 2 years

  19. Time to Maximum concentration (Tmax)

    PK parameters of CYP3A4 probe substrate midazolam with and without PF-07994525

    Time frame: From the first day through 30-37 days after the last study treatment, up to approximately 2 years

  20. Maximum Observed Concentration (Cmax)

    PK parameters of CYP3A4 probe substrate midazolam with and without PF-07994525

    Time frame: From the first day through 30-37 days after the last study treatment, up to approximately 2 years

07

Study locations

29 of 30 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

09

Timeline

3 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jul 2026 (actual). Primary completion is estimated for Jul 2029, 36 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 16, 2026
First posted
Feb 23, 2026
StartActual
Jul 1, 2026
Primary completionEst.
Jul 10, 2029
CompletionEst.
Jul 10, 2030
Last update
Nov 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
11 sites added
Show 11 added (10 United States, 1 Canada)
  • Colorado Blood Cancer Institute · Denver, United States
  • Presbyterian/St. Luke's Medical Center · Denver, United States
  • Smilow Cancer Hospital - Yale New Haven Health · New Haven, United States
  • Yale-New Haven Hospital-Yale Cancer Center · New Haven, United States
  • Smilow Cancer Hospital Phase 1 Unit · New Haven, United States
  • Yale University - Smilow Cancer Hospital; C/O Thomas Ferencz, RPh, BCOP · New Haven, United States
  • Smilow Cancer Hospital - North Haven · North Haven, United States
  • Ohio State University Hospitals · Columbus, United States
  • The James Cancer Hospital and Solove Research Institute · Columbus, United States
  • The James Outpatient Care West Campus · Columbus, United States
  • Juravinski Cancer Centre · Hamilton, Canada
across 3 updates, Sep 25, 2026 – Nov 5, 2026
Show all 3 updates
  1. Nov 5, 2026
    4 sites added
    Show 4 added (3 United States, 1 Canada)
    • Ohio State University Hospitals · Columbus, United States
    • The James Cancer Hospital and Solove Research Institute · Columbus, United States
    • The James Outpatient Care West Campus · Columbus, United States
    • Juravinski Cancer Centre · Hamilton, Canada
    + 1 other change: verification date
  2. Oct 13, 2026
    5 sites added
    Show 5 added (5 United States)
    • Smilow Cancer Hospital - Yale New Haven Health · New Haven, United States
    • Yale-New Haven Hospital-Yale Cancer Center · New Haven, United States
    • Smilow Cancer Hospital Phase 1 Unit · New Haven, United States
    • Yale University - Smilow Cancer Hospital; C/O Thomas Ferencz, RPh, BCOP · New Haven, United States
    • Smilow Cancer Hospital - North Haven · North Haven, United States
    + 1 other change: verification date
  3. Sep 25, 2026
    2 sites added
    Show 2 added (2 United States)
    • Colorado Blood Cancer Institute · Denver, United States
    • Presbyterian/St. Luke's Medical Center · Denver, United States

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07426757
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Feb 23, 2026
Start date
Jul 1, 2026
Primary completion
Jul 10, 2029 (estimated)
Completion
Jul 10, 2030 (estimated)
Last update
Nov 5, 2026

Study contacts

Pfizer CT.gov Call Center
Contact
ClinicalTrials.gov_Inquiries@pfizer.com
1-800-718-1021
Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion